Literature DB >> 15110329

Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts.

Thomas Lücke1, Wiebke Höppner, Esther Schmidt, Sabine Illsinger, Anibh M Das.   

Abstract

UNLABELLED: Fabry disease (FD, MIM 301500) caused by a deficient activity of alpha-galactosidase A is characterized by intralysosomal storage of glycosphingolipids. Main clinical features are paresthesia, hypohidrosis, angiokeratoma, renal insufficiency, and cardiovascular or cerebral complications. The exact pathogenesis is unclear. Beside mechanical storage biochemical factors might play a role. As FD is a multisystemic disorder and mitochondrial dysfunction has been described in patients with neuronal ceroidlipofuscinosis (another lysosomal storage disease) we examined mitochondrial function in fibroblasts from patients with FD.
RESULTS: Activities of respiratory chain enzymes I, IV, and V were significantly (p < 0.01) lower in FD-cells. Mitochondrial recovery was unchanged as judged by the activity of the mitochondrial marker enzyme citratesynthase, cellular protein content was not significantly different. CP, ADP, and AMP concentrations were significantly (p < 0.01) lower in FD-cells. ATP was slightly, but not significantly reduced (p = 0.045).
CONCLUSION: Organ dysfunction in FD may not only be explained by mechanical storage of glycosphingolipids. As in NCL, lysosomal storage material may lead to mitochondrial dysfunction with a reduction of respiratory chain enzyme activities and a subsequent drop in cellular levels of energy-rich phosphates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110329     DOI: 10.1016/j.ymgme.2004.01.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  29 in total

Review 1.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

Review 2.  Sphingolipids and mitochondrial apoptosis.

Authors:  Gauri A Patwardhan; Levi J Beverly; Leah J Siskind
Journal:  J Bioenerg Biomembr       Date:  2016-04       Impact factor: 2.945

3.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

Review 4.  Neurodevelopmental manifestations of mitochondrial disease.

Authors:  Marni J Falk
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

Review 5.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

Review 6.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

Review 7.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

8.  Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.

Authors:  Metodi V Stankov; Thomas Lücke; Anibh M Das; Reinhold E Schmidt; Georg M N Behrens
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

Review 9.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

10.  Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.

Authors:  Jonathan C P Roos; Matthew J Daniels; Elizabeth Morris; Hanna I Hyry; Timothy M Cox
Journal:  Mol Genet Metab       Date:  2017-06-21       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.